By Carlos Villatoro
Imagine a world where maladies such as cystic fibrosis, Huntington’s Disease, or sickle cell anemia no longer exist. While the U.S. is far from achieving this lofty goal, it recently came a step closer at the California National Primate Research Center (CNPRC), where scientists have efficiently used CRISPR/Cas9 technology to modify the genes of rhesus macaque embryos.
The research, recently published in the latest edition of Human Molecular Genetics, paves the way for future studies where the possibility of birthing gene-edited monkeys that can serve as models for new therapies is greatly increased.
Event Includes Horse Therapies For First Time
By Pat Bailey
Four UC Davis researchers with expertise in the application of stem cell science for therapies in human or veterinary medicine are slated to speak during the World Stem Cell Summit in Palm Beach, Florida, Dec. 6-9.
UC Davis researchers are exploring stem cell technology to treat both horses and humans. Photo by Karin Higgins/UC Davis.
This will be the 12th consecutive year that the summit has brought together scientists, physicians and veterinarians, industry representatives and patient advocates from around the world to share medical breakthroughs in stem cell research, also known as regenerative medicine.
[Contributed by Holly Ober, Biomedical Engineering]
Transplanted liver cells could repair livers damaged by toxins or infections. Stem cells hold tremendous promise for liver-related therapies because they can grow in a Petri dish to become any cell type, including liver cells. However, scientists have yet to identify the best reagents to add into the Petri dish to push stem cells to become liver cells. An expensive and time-consuming process of trial and error guides the discovery of reagents and signals for stem cell differentiation. Now, a team of biomedical engineers led by Prof. Alexander Revzin at UC Davis has found a way to grow liver cells from stem cells more cheaply and effectively than current methods.
Full post: Printed spots for growing liver stem cells
(398 words, 1 image, estimated 1:36 mins reading time)
The most complete version to date of the mouse genome was published yesterday in the journal PLoS Biology. “Build 36,” from the C57 inbred strain of black mice, has 175,000 fewer gaps, 139 megabytes of new sequences and realigns genes that were incorrectly described in an earlier version of the mouse genome.
The new genome map predicts just over 20,000 protein-coding genes in the mouse. About 75 percent of these are 1:1 “orthologs” or counterparts of human genes. The authors note that about 5,000 of these genes can be studied in “knockout” mice.
Full post: Final mouse genome published
(291 words, estimated 1:10 mins reading time)
Therapy restores blood flow in mice, forms the basis for upcoming clinical trials in humans
(SACRAMENTO, Calif.) — Researchers have successfully induced the formation of new blood vessels in mice with reduced blood flow (ischemia) to their limbs using adult human stem cells. The breakthrough treatment resulted in fully functioning limbs that showed both increased blood flow to previously damaged areas and an increase in the number of blood vessels. The study, published in this week’s print edition of the journal Blood, paves the way for the stem cell-based treatment of peripheral arterial disease (PAD) in humans, a painful condition common in diabetic patients that can lead to amputation.
Four UC Davis stem cell experts will give brief presentations on stem cell research followed by question-and-answer sessions during a community forum on Tuesday, May 12 from 5:30 to 7:30 p.m. at the UC Davis Cancer Center auditorium, 4501 X Street, in Sacramento.
The event, which is free and open to the public, is the first in a series of three discussions entitled “Stem Cell Dialogues,” which offer opportunities for the public to learn about the stem cell therapies UC Davis is developing to potentially treat and cure a wide array of disease and injury. With limited seating, those interested in attending this first session should reserve seats by contacting Michele Steiner at firstname.lastname@example.org or calling her at 916-734-9116.
Paul Knoepfler, an assistant professor of cell biology and human anatomy at the UC Davis School of Medicine, has been awarded a grant of $2 million over five years to support his work on how embryonic stem cells are programmed.
Embryonic stem cells and induced pluripotent stem cells are promising for medical purposes because they can develop into a wide range of tissues. But they can also give rise to tumors in mice. Knoepfler is studying the genetic mechanisms that control whether a stem cell develops properly, or forms a tumor.
Full post: Grant for stem cell researcher
(139 words, estimated 33 secs reading time)
UC Davis has been awarded a $20 million grant from the California Institute of Regenerative Medicine, the state’s stem cell research agency, towards renovating an existing building to house the rapidly growing stem cell research program.
The building will eventually have 100,000 square feet of space. It will include research labs and support facilities, as well as a “Good Manufacturing Practice” (GMP) facility for the development of FDA-approved cellular therapies.
Full post: $20 million stem cell grant
(188 words, estimated 45 secs reading time)
LiveScience.com reports on a San Diego company offering a stem cell therapy to treat arthritis, tendon and ligament problems in dogs. A veterinarian removes some fat from the dog and ships it to the company, which extracts adult stem cells from the fatty tissue and returns them in a ready-to-use syringe. Presumably, the idea is that these are stem cells that can fairly readily turn into connective tissue and repair damage.
“We’ve seen stem cell therapy help dogs whose pain was previously so severe that they struggled to stand, jump into cars, chase balls or run up and down stairs,” said Robert Harman, DVM, and founder of Vet-Stem.
Full post: Stem cell therapy for animals
(270 words, estimated 1:05 mins reading time)
UC Davis stem cell scientist Chong-xian Pan has received a new faculty award from the California Institute for Regenerative Medicine. The award will provide Pan with $2.4 million over five years for salary and research support.
Pan, who specializes in cancer and blood diseases, is both a physician and a Ph.D. scientist. His current research is focused on stem cell approaches that could be used to help cancer patients overcome leukemia.
The award was among $54 million in grants announced by CIRM December 12.
Permanent link to this post
(86 words, estimated 21 secs reading time)